The use of monoclonal antibody immunoconjugates in cancer therapy.
Pietersz
G A
GA
Austin Research Institute, Austin Hospital, Heidelberg, Vic., Australia.
Krauer
K
K
McKenzie
I F
IF
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D002986:Clinical Trials as Topic; D006801:Humans; D018796:Immunoconjugates / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D000922:Immunotoxins / Q000627:therapeutic use; D008562:Membrane Glycoproteins / Q000276:immunology; D018396:Mucin-1; D009077:Mucins / Q000276:immunology; D009363:Neoplasm Proteins / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D016499:Radioimmunotherapy
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000922:Immunotoxins; D008562:Membrane Glycoproteins; D018396:Mucin-1; D009077:Mucins; D009363:Neoplasm Proteins